A Randomized, Double-blind, Placebo-controlled Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Single Intravenous and Subcutaneous Doses of GZ402668 in Men and Women With Progressive Multiple Sclerosis

Trial Profile

A Randomized, Double-blind, Placebo-controlled Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Single Intravenous and Subcutaneous Doses of GZ402668 in Men and Women With Progressive Multiple Sclerosis

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs GZ 402668 (Primary) ; GZ 402668 (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; First in man
  • Sponsors Genzyme Corporation
  • Most Recent Events

    • 28 Apr 2017 Results (n=44) presented at the 69th Annual Meeting of the American Academy of Neurology.
    • 02 Mar 2016 Planned End Date changed from 1 Feb 2016 to 1 Mar 2016, as reported by ClinicalTrials.gov.
    • 02 Mar 2016 Planned primary completion date changed from 1 Feb 2016 to 1 Mar 2016, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top